Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.~The participant:~* Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age;~* Has a body mass index (BMI) \> 20 kg/m\^2 and \< 43 kg/m\^2; for Japan: BMI \>18 kg/m\^2 and \<43 kg/m\^2;~* Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks) or is on oral AHA therapy but has inadequate glycemic control;~* Is a male, or a female who is highly unlikely to conceive.~Exclusion Criteria:~If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.~The participant:~* Has a history of type 1 diabetes mellitus or a history of ketoacidosis;~* Is on a weight loss program or has started a weight loss medication within the prior 8 weeks;~* Has required insulin therapy within 14 weeks prior to signing informed consent;~* Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease;~* Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease;~* Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder;~* Has a history of malignancy or clinically important hematological disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Omarigliptin 0.25 mg (Base) (Type: EXPERIMENTAL): Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
- Omarigliptin 1 mg (Base) (Type: EXPERIMENTAL): Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
- Omarigliptin 3 mg (Base) (Type: EXPERIMENTAL): Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
- Omarigliptin 10 mg (Base) (Type: EXPERIMENTAL): Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
- Omarigliptin 25 mg (Base) (Type: EXPERIMENTAL): Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
- Placebo (Base) (Type: PLACEBO_COMPARATOR): Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
- Pooled omarigliptin (Extension) (Type: EXPERIMENTAL): Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
- Placebo/Metformin (Type: ACTIVE_COMPARATOR): Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).